The blood-brain-barrier (BBB) is a significant obstacle for treating many neurological disorders. Bubble-assisted focused ultrasound (BAFUS) medicated BBB disruption is a promising technology that enables the delivery of large drug doses at targeted locations across the BBB. However, the current lack of an in vitro model of this process hinders the full understanding of BAFUS BBB disruption for better translation into clinics. In this work, a US-transparent organ-on-chip device has been fabricated that can be critical for the in vitro modeling of the BAFUS BBB disruption. The transparency of the device window to focused ultrasound (FUS) was calculated theoretically and demonstrated by experiments. Nanobubbles were fabricated, characterized by cryogenic transmission electron microscopy (cryo-TEM), and showed bubble cavitation under FUS. Human colorectal adenocarcinoma (Caco-2) cells were used to form a good cellular barrier for BAFUS barrier disruption, as suggested by the measured permeability and transepithelial electrical resistance (TEER). Finally, barrier disruption and recovery were observed in BAFUS disrupted US-transparent organ-on-chips with Caco-2 barriers, showing great promise of the platform for future modeling BAFUS BBB disruption in vitro.

Mass nuclear catastrophe is a serious concern for society at large when considering the rising threat of terrorism and the risks associated with harnessing nuclear energy. In the case of a mass nuclear/radiological event that requires hundreds of thousands of individuals to be assessed for radiation exposure, a rapid biodosimetry triage tool is crucial [1]. The Cytokinesis Block Micronucleus Assay (CBMN) is a promising cytogenetic biodosimetry assay for triage [2]; however, it requires shipping samples to a central laboratory (1-3 days) followed by a lengthy cell culture process (~3 days) before the first dose estimate can be available. The total ~ 1 week response time is too long for effective medical care intervention. A shipping incubator could cut the response time in half (~3 days) by culturing samples in transit; however, possible shipping delays beyond 2 days without the addition of a necessary reagent (Cyto-B) would ruin the integrity of the samples—for accurate CBMN assay endpoint observation, Cyto-B must be added within a 24-44 hour window after sample culture is initiated. Here, we propose a “Smart” Shipping Incubator (SSI) that can add Cyto-B while samples are in transit through a centrifugal system equipped with microfluidic capillary valve caps. The custom centrifugal system was constructed with CNC machined and 3D printed plastic parts, controlled by a custom printed circuit board (PBC) microcontroller, and housed inside a commercial shipping incubator (iQ5 from MicroQ Technologies). Teflon-coated, pre-pulled glass micropipettes (FivePhoton BioChemicals) were used as microfluidic capillary valve caps. Release of Cyto-B was characterized by a desktop centrifugal system at different tip sizes and relative centrifugal forces (RCFs). A theoretical model of Cyto-B release was also deduced to aid the optimization of the process. The CBMN assay was conducted both in the SSI with centrifugal Cyto-B release and in a standard CO2 incubator with manual addition of Cyto-B as the control. The expected mechanical shock during shipment was measured to be less than 25g. Optimal Cyto-B release was found to be at 35g RCF with a Teflon-coated 40 µm tip. Similar CBMN dose curves of micronuclei per binucleated cells (MN/BN) vs. exposed radiation (Gy) were produced for samples assessed conventionally and with the SSI. The similarities between the two methods suggest that centrifugation does not significantly affect the CBMN assay.